Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients
Clinical & Experimental Allergy · 2025
DOI: 10.1111/cea.70184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von Julia Eckl-Dorna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Aspirin, Anti-Inflammatory Agents, Non-Steroidal, Nasal Mucosa. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease (N‐ERD) is characterised by the clinical triad of hypersensitivity to NSAIDs, nasal polyposis, and asthma. The cells and mediators causing acute symptoms when driving the hypersensitivity reaction to acetylsalicylic acid (ASA) ingestion, remain poorly defined.
Objective
To investigate the dynamics of nasal mediators during ASA provocation in N‐ERD patients before and 24 weeks after therapy with the IL‐4 receptor alpha‐blocking antibody dupilumab (EudraCT (2019‐004889‐18) and ClinicalTrials.gov (NCT04442256)).
Methods
Nasal mucosal lining fluids of patients with N‐ERD, chronic rhinosinusitis patients with nasal polyp (CRSwNP) and healthy disease controls were collected at selected time points up to 2 h after ASA provocation. Analysis of thirty‐three different inflammatory mediators as well as transcriptomic profiling was performed. In N‐ERD patients, provocation was repeated after 24 weeks of dupilumab therapy.
Results
Sixty minutes after provocation with ASA, N‐ERD patients showed a significant increase in type 2 associated cytokines (i.e., TSLP, IL‐5 and eotaxin‐3) as compared to the other patient groups. This effect was diminished after 24 weeks of dupilumab therapy and was independent of the development of ASA tolerance. Transcriptomics revealed dampened upregulation of type 2 associated pathway genes (i.e., AREG ) as well as enhanced downregulation of lipid (i.e., ALOX15 ) and peroxisome metabolisms (i.e., NOS2 ) at ASA provocation after dupilumab therapy. Conclusion and Clinical Relevance Treatment with dupilumab leads to reduced nasal type 2 cytokine secretion and distinct changes in transcriptomic profile during ASA provocation, but changes in type 2 mediators show no association with tolerance development. Trial Registration EudraCT (2019‐004889‐18) and ClinicalTrials.gov (NCT04442256)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
- Department of Dermatology, General Hospital and Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Julia Eckl-Dorna, Christina Morgenstern, Aldine Tu, Sven Schneider
Zitieren
APA
Eckl-Dorna, J., Morgenstern, C., Poglitsch, K., Arnoldner, T., Gangl, K., Bartosik, T. J., Campion, N. J., Tu, A., Stanek, V., Schneider, S., & Bangert, C. (2025). Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70184
Vancouver
Eckl-Dorna J, Morgenstern C, Poglitsch K, Arnoldner T, Gangl K, Bartosik TJ, et al. Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70184
BibTeX
@article{EcklDorna2025,
author = {Eckl-Dorna, Julia and Morgenstern, Christina and Poglitsch, Katharina and Arnoldner, Tamara and Gangl, Katharina and Bartosik, Tina J and Campion, Nicholas J and Tu, Aldine and Stanek, Victoria and Schneider, Sven and Bangert, Christine},
title = {Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients},
journal = {Clinical & Experimental Allergy},
year = {2025},
doi = {10.1111/cea.70184}
}
EUVIMED